Abstract
COVID-19 has impacted billions of people since 2019 and unfolded a major healthcare crisis. With an increasing number of deaths and the emergence of more transmissible variants, it is crucial to better understand the biology of the disease-causing virus, the SARS-CoV-2. Peripheral neuropathies appeared as a specific COVID-19 symptom occurring at later stages of the disease. In order to understand the impact of SARS-CoV-2 on the peripheral nervous system, we generated human sensory neurons from induced pluripotent stem cells that we infected with the SARS-CoV-2 strain WA1/2020 and the variants delta and omicron. Using single-cell RNA sequencing, we found that human sensory neurons can be infected by SARS-CoV-2 but are unable to produce infectious viruses. Our data indicate that sensory neurons can be infected by the original WA1/2020 strain of SARS-CoV-2 as well as the delta and omicron variants, yet infectability differs between the original strain and the variants.
Original language | English |
---|---|
Article number | 107690 |
Journal | iScience |
Volume | 26 |
Issue number | 9 |
DOIs | |
State | Published - 15 Sep 2023 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2023 The Authors
Funding
We thank members in the laboratories of Rudolf Jaenisch and Richard Young and other colleagues from Whitehead Institute and MIT for helpful discussions and resources. We thank Wendy Salmon from the Whitehead W.M. Keck Microscopy Facility and Whitehead Genome Core Facility. This work was supported by grants from the NIH (U19AI131135 and R01MH104610). This work was performed in part in the Ragone Institute BSL3 core, which is supported by the NIH-funded Harvard University Center for AIDS Research (P30 AI060354). Project design by A.F.; execution of experiments by A.F. P.B. A.R. and D.T.; data analysis by A.F. A.R. and D.T.; manuscript preparation by A.F. P.B. A.R. D.T. and R.J. R.J. is an advisor/co-founder of Fate Therapeutics, Fulcrum Therapeutics, Omega Therapeutics, and Paratus Therapeutics. A.F. is a co-founder and shareholder of StemAxon. All other authors declare no competing interests. We support inclusive, diverse, and equitable conduct of research. We thank members in the laboratories of Rudolf Jaenisch and Richard Young and other colleagues from Whitehead Institute and MIT for helpful discussions and resources. We thank Wendy Salmon from the Whitehead W.M. Keck Microscopy Facility and Whitehead Genome Core Facility. This work was supported by grants from the NIH ( U19AI131135 and R01MH104610 ). This work was performed in part in the Ragone Institute BSL3 core, which is supported by the NIH -funded Harvard University Center for AIDS Research ( P30 AI060354 ).
Funders | Funder number |
---|---|
Fate Therapeutics | |
Fulcrum Therapeutics | |
Omega Therapeutics | |
Paratus Therapeutics | |
National Institutes of Health | U19AI131135, R01MH104610 |
Massachusetts Institute of Technology | |
Harvard University Center for AIDS Research | P30 AI060354 |
Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology |
Keywords
- Cellular neuroscience
- Neuroscience
- Virology